[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:polycythemia-vera-post-polycythemic-myelofibrosis-phase":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":80,"states":81},"Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase",11,8,[8,16,23,29,35,41,48,54,60,67,74],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06773195","A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:17:33.002248Z","2026-07-30T01:46:14.433209Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07357727","A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)",[20],"Phase 3","2026-08-26T02:16:22.235886Z","2026-05-13T02:55:06.696964Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT06327100","Open Label Phase 1\u002F2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)",[12],"2026-08-26T02:17:22.949982Z","2026-05-05T02:43:28.983524Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":14,"content_modified":34},"NCT06343805","A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)",[33],"Phase 1","2026-05-05T02:43:28.652465Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT05280509","Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib",[12],"2026-08-26T02:16:36.513735Z","2026-05-05T02:43:28.627507Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":46,"content_modified":47},"NCT06517875","Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis",[45],"Phase 2","2026-08-26T02:19:10.436356Z","2026-05-05T02:43:27.178210Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT06291987","Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation",[33],"2026-08-26T02:15:21.365312Z","2026-05-05T02:43:27.513961Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT06218628","Pacritinib w\u002F Talazoparib in Pts w\u002F Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition",[33],"2026-08-26T02:16:24.135291Z","2026-05-05T02:35:31.622551Z",{"nct_id":61,"title":62,"phases":63,"status":64,"updated_at":65,"content_modified":66},"NCT07734077","Revumenib in Patients With Myelofibrosis",[12],"NOT_YET_RECRUITING","2026-08-26T02:19:17.380174Z","2026-07-30T01:46:14.457646Z",{"nct_id":68,"title":69,"phases":70,"status":71,"updated_at":72,"content_modified":73},"NCT03165734","A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis",[20],"ACTIVE_NOT_RECRUITING","2026-08-03T00:52:55.795520Z","2026-05-05T02:47:14.272170Z",{"nct_id":75,"title":76,"phases":77,"status":71,"updated_at":78,"content_modified":79},"NCT05467800","Study of Canakinumab in Patients With Myelofibrosis",[45],"2026-08-03T03:32:35.491916Z","2026-05-05T02:43:27.753728Z",[],[82,86,89],{"state":83,"count":84,"slug":85},"New York",5,"new-york",{"state":87,"count":84,"slug":88},"Ohio","ohio",{"state":90,"count":91,"slug":92},"Texas",4,"texas"]